|
Jun 17
|
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
|
|
Jun 14
|
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
|
|
Jun 14
|
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
|
|
May 14
|
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
|
|
May 14
|
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
|
|
May 12
|
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
|
May 10
|
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
|
|
May 9
|
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
|
|
May 9
|
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
|
|
May 9
|
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
|
|
May 9
|
Editas Medicine First Quarter 2024 Earnings: Misses Expectations
|
|
May 9
|
Q1 2024 Editas Medicine Inc Earnings Call
|
|
May 8
|
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 8
|
Editas Medicine Announces First Quarter 2024 Results and Business Updates
|
|
May 5
|
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
|
|
May 2
|
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
|
|
May 1
|
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
|
|
Apr 29
|
12 Under-the-Radar Stocks With Massive Upside for 2024
|
|
Apr 26
|
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 22
|
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
|